Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.

Tahara A, Takasu T.

Endocr Res. 2020 Jan 18:1-15. doi: 10.1080/07435800.2020.1713802. [Epub ahead of print]

PMID:
31955626
3.

Donor-Acceptor π-Conjugated Enamines: Functional Group-Compatible Synthesis from Amides and Their Photoabsorption and Photoluminescence Properties.

Tahara A, Kitahara I, Sakata D, Kuninobu Y, Nagashima H.

J Org Chem. 2019 Dec 6;84(23):15236-15254. doi: 10.1021/acs.joc.9b02267. Epub 2019 Nov 11.

PMID:
31657210
4.

Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients.

Tahara N, Nitta Y, Bekki M, Tahara A, Maeda-Ogata S, Sugiyama Y, Honda A, Igata S, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Matsui T, Yamagishi SI, Fukumoto Y.

J Nucl Cardiol. 2019 Aug 12. doi: 10.1007/s12350-019-01842-5. [Epub ahead of print]

PMID:
31407236
5.

Risk indicators for marginal bone resorption around implants in function for at least 4 years: A retrospective longitudinal study.

Mameno T, Wada M, Otsuki M, Okuno I, Ozeki K, Tahara A, Ikebe K.

J Periodontol. 2020 Jan;91(1):37-45. doi: 10.1002/JPER.18-0756. Epub 2019 Nov 14.

PMID:
31373383
6.

Effects of 8 weeks of masticatory muscles focused endurance exercises on women with oro-facial pain and temporomandibular disorders: A placebo randomised controlled trial.

Barbosa MA, Tahara AK, Ferreira IC, Intelangelo L, Barbosa AC.

J Oral Rehabil. 2019 Oct;46(10):885-894. doi: 10.1111/joor.12823. Epub 2019 May 31.

PMID:
31099036
7.

Clinical hallmarks making diagnosis of infective endocarditis.

Tahara A, Tahara N, Maeda-Ogata S, Bekki M, Sugiyama Y, Sun J, Honda A, Igata S, Fukumoto Y.

J Nucl Cardiol. 2019 Mar 18. doi: 10.1007/s12350-019-01686-z. [Epub ahead of print] No abstract available.

PMID:
30887385
8.

Signal intensity of superb micro-vascular imaging associates with the activity of vascular inflammation in Takayasu arteritis.

Ito S, Tahara N, Hirakata S, Kaieda S, Tahara A, Maeda-Ogata S, Bekki M, Sugiyama Y, Honda A, Igata S, Kuromatsu R, Nakashima O, Fukumoto Y.

J Nucl Cardiol. 2019 Mar 4. doi: 10.1007/s12350-019-01665-4. [Epub ahead of print] No abstract available.

PMID:
30834495
9.

In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.

Takasu T, Yokono M, Tahara A, Takakura S.

Biol Pharm Bull. 2019;42(3):507-511. doi: 10.1248/bpb.b18-00728.

10.

Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine.

Tahara N, Kojima R, Yoshida R, Bekki M, Sugiyama Y, Tahara A, Maeda S, Honda A, Igata S, Nakamura T, Sun J, Matsui T, Fukumoto Y, Matsui T, Yamagishi SI.

Rejuvenation Res. 2019 Oct;22(5):431-438. doi: 10.1089/rej.2018.2152. Epub 2019 Mar 28.

PMID:
30661488
11.

Hydration of Polycationic [5]Radialene with Quintuple 1,3-Dithiol-2-ylidenes Leads to a New Class of π-Extended Tetrathiafulvalene Scaffold.

Ueda M, Tahara A, Hasegawa M, Shirahata T, Mazaki Y, Misaki Y.

Chemistry. 2019 Apr 1;25(19):4984-4991. doi: 10.1002/chem.201805994. Epub 2019 Mar 4.

PMID:
30636026
12.

Utility of the amplitude of RV1+SV5/6 in assessment of pulmonary hypertension.

Igata S, Tahara N, Sugiyama Y, Bekki M, Kumanomido J, Tahara A, Honda A, Maeda S, Nashiki K, Nakamura T, Sun J, Abe T, Fukumoto Y.

PLoS One. 2018 Nov 26;13(11):e0206856. doi: 10.1371/journal.pone.0206856. eCollection 2018.

13.

Remarkably high catalyst efficiency of a disilaruthenacyclic complex for hydrosilane reduction of carbonyl compounds.

Tahara A, Sunada Y, Takeshita T, Inoue R, Nagashima H.

Chem Commun (Camb). 2018 Oct 2;54(79):11192-11195. doi: 10.1039/c8cc04780d.

PMID:
30229241
14.

Importance of extracardiac FDG uptake to diagnose cardiac sarcoidosis.

Tahara N, Bekki M, Sugiyama Y, Tahara A, Fukumoto Y.

J Nucl Cardiol. 2018 Sep 5. doi: 10.1007/s12350-018-1425-2. [Epub ahead of print] No abstract available.

PMID:
30187240
15.

Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.

Tahara A, Kondo Y, Takasu T, Tomiyama H.

Biomed Pharmacother. 2018 Sep;105:1033-1041. doi: 10.1016/j.biopha.2018.06.062. Epub 2018 Jun 19.

PMID:
30021338
16.

Diagnostic performance of FDG-PET/CTA in native mitral valve endocarditis.

Maeda S, Tahara N, Takase F, Bekki M, Tahara A, Honda A, Igata S, Sugiyama Y, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Fukumoto Y.

J Nucl Cardiol. 2019 Apr;26(2):681-683. doi: 10.1007/s12350-018-1321-9. Epub 2018 Jun 5. No abstract available.

PMID:
29872968
17.

Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.

Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI.

Curr Vasc Pharmacol. 2019;17(4):411-420. doi: 10.2174/1570161116666180515154555.

PMID:
29766812
18.

Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.

Tahara A, Takasu T.

Eur J Pharmacol. 2018 Jul 5;830:68-75. doi: 10.1016/j.ejphar.2018.04.024. Epub 2018 Apr 25.

PMID:
29702076
19.

Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease.

Bekki M, Tahara N, Tahara A, Honda A, Igata S, Sugiyama Y, Nakamura T, Sun J, Kurata S, Fujimoto K, Abe T, Tanaka H, Suda K, Fukumoto Y.

J Nucl Cardiol. 2019 Apr;26(2):671-673. doi: 10.1007/s12350-018-1278-8. Epub 2018 Apr 17. No abstract available.

PMID:
29667011
20.

Disilaruthena- and Ferracyclic Complexes Containing Isocyanide Ligands as Effective Catalysts for Hydrogenation of Unfunctionalized Sterically Hindered Alkenes.

Sunada Y, Ogushi H, Yamamoto T, Uto S, Sawano M, Tahara A, Tanaka H, Shiota Y, Yoshizawa K, Nagashima H.

J Am Chem Soc. 2018 Mar 21;140(11):4119-4134. doi: 10.1021/jacs.8b00812. Epub 2018 Mar 9.

PMID:
29505246
21.

Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.

Tahara A, Takasu T.

Life Sci. 2018 Mar 15;197:80-90. doi: 10.1016/j.lfs.2018.02.009. Epub 2018 Feb 6.

PMID:
29425766
22.

Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.

Tahara A, Takasu T.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):395-406. doi: 10.1007/s00210-018-1469-5. Epub 2018 Jan 26.

PMID:
29374293
23.

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

Eur J Pharmacol. 2018 Jan 5;818:545-553. doi: 10.1016/j.ejphar.2017.11.020. Epub 2017 Nov 16.

PMID:
29154936
24.

Cardioprotection by minocycline in a rabbit model of ischemia/reperfusion injury: Detection of cell death by in vivo 111In-GSAO SPECT.

Yamaki T, de Haas HJ, Tahara N, Petrov A, Mohar D, Haider N, Zhou J, Tahara A, Takeishi Y, Boersma HH, Scarabelli T, Kini A, Strauss HW, Narula J.

J Nucl Cardiol. 2018 Feb;25(1):94-100. doi: 10.1007/s12350-017-1031-8. Epub 2017 Aug 24.

PMID:
28840574
25.

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

Eur J Pharmacol. 2017 Aug 15;809:163-171. doi: 10.1016/j.ejphar.2017.05.019. Epub 2017 May 12.

PMID:
28506912
26.

Right ventricular workload assessed by FDG-PET in a patient with residual VSD and infundibular pulmonary stenosis after repair of tetralogy of Fallot.

Nakamura T, Tahara N, Tahara A, Honda A, Igata S, Bekki M, Sugiyama Y, Sun J, Kumagai E, Kurata S, Fujimoto K, Abe T, Kato S, Tanaka H, Fukumoto Y.

J Nucl Cardiol. 2018 Jun;25(3):1053-1055. doi: 10.1007/s12350-017-0906-z. Epub 2017 May 1. No abstract available.

PMID:
28462468
27.

Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects.

Tahara A, Tahara N, Yamagishi SI, Honda A, Igata S, Nitta Y, Bekki M, Nakamura T, Sugiyama Y, Sun J, Takeuchi M, Shimizu M, Yamazaki H, Fukami K, Fukumoto Y.

Int J Food Sci Nutr. 2017 Dec;68(8):1013-1020. doi: 10.1080/09637486.2017.1318117. Epub 2017 Apr 23.

PMID:
28434257
28.

Myocardial metabolic improvement prior to electrocardiographic or volumetric changes of the right ventricle in pulmonary arterial hypertension.

Nakamura T, Tahara N, Tahara A, Honda A, Bekki M, Sugiyama Y, Sun J, Kumagai E, Kurata S, Fujimoto K, Abe T, Igata S, Fukumoto Y.

J Nucl Cardiol. 2018 Feb;25(1):358-359. doi: 10.1007/s12350-016-0769-8. Epub 2017 Jan 3. No abstract available.

PMID:
28050862
29.

Theoretical Study of the Catalytic Hydrogenation of Alkenes by a Disilaferracyclic Complex: Can the Fe-Si σ-Bond-Assisted Activation of H-H Bonds Allow Development of a Catalysis of Iron?

Tahara A, Tanaka H, Sunada Y, Shiota Y, Yoshizawa K, Nagashima H.

J Org Chem. 2016 Nov 18;81(22):10900-10911. Epub 2016 Oct 17.

PMID:
27704834
30.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

J Pharmacol Sci. 2016 Jul;131(3):198-208. doi: 10.1016/j.jphs.2016.06.004. Epub 2016 Jun 29.

31.

Vascular Inflammation Evaluated by [18F]-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Is Associated With Endothelial Dysfunction.

Honda A, Tahara N, Nitta Y, Tahara A, Igata S, Bekki M, Nakamura T, Sugiyama Y, Kaida H, Kurata S, Fujimoto K, Abe T, Enomoto M, Adachi H, Narula J, Yamagishi S, Fukumoto Y.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1980-8. doi: 10.1161/ATVBAHA.116.307293. Epub 2016 Jul 7.

PMID:
27386941
32.

Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.

Tahara N, Yamagishi SI, Bekki M, Kodama N, Nakamura T, Sugiyama Y, Oshige T, Kumashiro Y, Honda A, Tahara A, Igata S, Fukumoto Y.

Curr Vasc Pharmacol. 2016;14(6):552-562.

PMID:
27357182
33.

In Vivo Molecular Imaging of Ruptured Coronary Atherosclerotic Plaque Using IVUS, OCT, and FDG-PET/CT.

Koiwaya H, Tahara N, Tahara A, Honda A, Igata S, Bekki M, Nakamura T, Sugiyama Y, Ohtsuka M, Kurata S, Fujimoto K, Abe T, Shibata Y, Ueno T, Fukumoto Y.

JACC Cardiovasc Interv. 2016 Jun 27;9(12):e113-5. doi: 10.1016/j.jcin.2016.03.013. Epub 2016 Jun 1. No abstract available.

34.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

J Pharmacol Sci. 2016 Mar;130(3):159-69. doi: 10.1016/j.jphs.2016.02.003. Epub 2016 Feb 15.

35.

FDG-PET/CT images during 5 years before acute aortic dissection.

Tahara N, Hirakata S, Okabe K, Tahara A, Honda A, Igata S, Kaida H, Abe T, Akashi H, Tanaka H, Fukumoto Y.

Eur Heart J. 2016 Jun 21;37(24):1933. doi: 10.1093/eurheartj/ehw075. Epub 2016 Mar 3. No abstract available.

PMID:
26941202
36.

Non-Precious-Metal Catalytic Systems Involving Iron or Cobalt Carboxylates and Alkyl Isocyanides for Hydrosilylation of Alkenes with Hydrosiloxanes.

Noda D, Tahara A, Sunada Y, Nagashima H.

J Am Chem Soc. 2016 Mar 2;138(8):2480-3. doi: 10.1021/jacs.5b11311. Epub 2016 Jan 13.

PMID:
26760915
37.

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

Arch Pharm Res. 2016 Feb;39(2):259-270. doi: 10.1007/s12272-015-0621-8. Epub 2015 Oct 8.

PMID:
26450351
38.

Potentially lethal pharyngolaryngeal edema with dyspnea in adult patients with mumps: A series of 5 cases.

Ohki M, Baba Y, Kikuchi S, Ohata A, Tsutsumi T, Tanaka S, Tahara A, Urata S, Ishikawa J.

Ear Nose Throat J. 2015 Apr-May;94(4-5):184-6.

PMID:
25923277
39.

Demonstration of the disease activity by serial carotid artery ultrasonography, magnetic resonance imaging and 18-fluoro-deoxyglucose positron emission tomography in a Behçet's disease patient with carotid artery stenosis.

Igata S, Tahara N, Tahara A, Honda A, Nitta Y, Kusaba K, Niiyama H, Kaida H, Abe T, Yoshiyama H, Fukumoto Y.

Eur Heart J. 2015 Jul 1;36(25):1629. doi: 10.1093/eurheartj/ehv031. Epub 2015 Feb 24. No abstract available.

PMID:
25713315
40.

Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.

Tahara N, Yamagishi S, Matsui T, Nishino Y, Honda A, Tahara A, Igata S, Fukumoto Y.

Int J Cardiol. 2015 Apr 1;184:14-6. doi: 10.1016/j.ijcard.2015.02.010. Epub 2015 Feb 10.

PMID:
25705004
41.

Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT.

Tahara N, Yamagishi S, Kodama N, Tahara A, Honda A, Nitta Y, Igata S, Matsui T, Takeuchi M, Kaida H, Kurata S, Abe T, Fukumoto Y.

J Clin Endocrinol Metab. 2015 May;100(5):E739-47. doi: 10.1210/jc.2014-3896. Epub 2015 Feb 19.

PMID:
25695885
42.

Positive correlation between malondialdehyde-modified low-density lipoprotein cholesterol and vascular inflammation evaluated by 18F-FDG PET/CT.

Kaida H, Tahara N, Tahara A, Honda A, Nitta Y, Igata S, Ishibashi M, Yamagishi S, Fukumoto Y.

Atherosclerosis. 2014 Dec;237(2):404-9. doi: 10.1016/j.atherosclerosis.2014.10.001. Epub 2014 Oct 2.

PMID:
25463065
43.

Noninvasive evaluation of bone-forming activity within the calcified atherosclerotic lesions by Tc 99m HMDP scintigraphy.

Tahara N, Tahara A, Honda A, Nitta Y, Igata S, Nakamura Y, Takeuchi Y, Akashi H, Tanaka H, Morioka M, Narula J, Yamagishi SI, Fukumoto Y.

JACC Cardiovasc Imaging. 2015 Jan;8(1):108-109. doi: 10.1016/j.jcmg.2014.05.018. Epub 2014 Nov 26. No abstract available.

44.

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.

Takasu T, Hayashizaki Y, Tahara A, Kurosaki E, Takakura S.

Clin Exp Pharmacol Physiol. 2015 Jan;42(1):87-93. doi: 10.1111/1440-1681.12317.

PMID:
25311502
45.

Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats.

Kondo M, Tahara A, Hayashi K, Abe M, Inami H, Ishikawa T, Ito H, Tomura Y.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Oct;387(10):909-19. doi: 10.1007/s00210-014-1023-z. Epub 2014 Jul 23.

PMID:
25052043
46.

Mobile left atrial round mass free floating in mitral regurgitation flow mimicking a whale spray.

Tahara A, Tahara N, Honda A, Imaizumi T.

BMJ Case Rep. 2014 Mar 11;2014. pii: bcr2013202725. doi: 10.1136/bcr-2013-202725. No abstract available.

47.

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

J Pharm Pharmacol. 2014 Jul;66(7):975-87. doi: 10.1111/jphp.12223. Epub 2014 Feb 17.

PMID:
24533859
48.

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y.

Eur J Pharmacol. 2014 Mar 15;727:66-74. doi: 10.1016/j.ejphar.2014.01.040. Epub 2014 Jan 30.

PMID:
24486393
49.

2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis.

Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, Tahara A, Constantinescu CC, Zhou J, Boersma HH, Imaizumi T, Nakano M, Finn A, Fayad Z, Virmani R, Fuster V, Bosca L, Narula J.

Nat Med. 2014 Feb;20(2):215-9. doi: 10.1038/nm.3437. Epub 2014 Jan 12.

PMID:
24412923
50.

Acute ST elevation myocardial infarction in an adult patient with anomalous origin of the left coronary artery from the pulmonary artery.

Omura T, Ogawa K, Hashimoto M, Kitada R, Ishikawa S, Koga Y, Koyama Y, Oda S, Izutani S, Tahara A.

J Cardiol Cases. 2014 Jan 2;9(3):121-123. doi: 10.1016/j.jccase.2013.12.002. eCollection 2014 Mar.

Supplemental Content

Loading ...
Support Center